Skip to main content

GH Guardant Health, Inc.

Healthcare

quality needs a look, discounted valuation.

Quality
Weak
Valuation
Cheaper
Key signals
52-week adjusted-price high Top-quintile 6-month momentum Filed revenue acceleration
183.10
183.1 Close (USD) Loading candles…

Is Guardant Health, Inc. a buy? Fundamentals and valuation first

  • Quality is weaker than peers. Operating margin is only around the 17th percentile. TTM ROE is about 239.2%.

  • Valuation is cheaper than most peers. TTM P/E is in the 6th percentile, lower than most liquid US common stocks.

  • Recent volatility is moderate. 60-day annualized volatility is near the 62th percentile. Average 20-day dollar volume is about $293.1M.

  • Signals are active now. 52-week adjusted-price high, Top-quintile 6-month momentum, Filed revenue acceleration currently holds; the tables below show what followed in this stock’s own history.

Watchlist

This page refreshes daily after the close. Add Guardant Health, Inc. to your watchlist to track signal changes on your next visit.

Historical evidence

Signals active now

Each active condition is tested against this stock’s own history and benchmarked versus the S&P 500.

52-week adjusted-price high

Active

Adjusted close first reaches a 252-trading-day high; repeated hits within 20 days count once.

13 historical occurrences (since 2020-09-14)
Average forward return after 52-week adjusted-price high。20-day: Win 75%, Sample 12, Median +7.17%, Excess +4.74%, Beat mkt rate 66.7%；60-day: Win 90.9%, Sample 11, Median +22.24%, Excess +23.4%, Beat mkt rate 90.9%；120-day: Win 90%, Sample 10, Median +20.21%, Excess +25.43%, Beat mkt rate 80%

120 days after: historical avg +35.05%

20-day +6.74%
60-day +26.17%
120-day +35.05%
20-day
60-day
120-day
Win
75%
90.9%
90%
Sample
12
11
10
Median
+7.17%
+22.24%
+20.21%
Excess
+4.74%
+23.4%
+25.43%
Beat mkt rate
66.7%
90.9%
80%

Over 10 occurrences, 120-day forward avg gained 35.05%, beat the market by 25.43 pts; win rate 90%.

Top-quintile 6-month momentum

Active · now 96.61016949152543%

The stock ranks in the top 20% of the liquid US common-stock universe by 126-day adjusted return.

27 historical occurrences (since 2019-04-08)
Average forward return after Top-quintile 6-month momentum。20-day: Win 63%, Sample 27, Median +6.21%, Excess +4.22%, Beat mkt rate 66.7%；60-day: Win 64%, Sample 25, Median +13.93%, Excess +9.94%, Beat mkt rate 48%；120-day: Win 58.3%, Sample 24, Median +11.93%, Excess +3.77%, Beat mkt rate 45.8%

120 days after: historical avg +14.42%

20-day +5.72%
60-day +15.74%
120-day +14.42%
20-day
60-day
120-day
Win
63%
64%
58.3%
Sample
27
25
24
Median
+6.21%
+13.93%
+11.93%
Excess
+4.22%
+9.94%
+3.77%
Beat mkt rate
66.7%
48%
45.8%

Over 24 occurrences, 120-day forward avg gained 14.42%, beat the market by 3.77 pts; win rate 58.3%.

Filed revenue acceleration

Active · now 39.56338275650004%

TTM revenue growth is at least 10% and improved versus the prior filed quarter; event date is the SEC filing date.

17 historical occurrences (since 2019-05-10)
Average forward return after Filed revenue acceleration。20-day: Win 52.9%, Sample 17, Median +9.96%, Excess +6.01%, Beat mkt rate 58.8%；60-day: Win 52.9%, Sample 17, Median +1.21%, Excess +8.37%, Beat mkt rate 52.9%；120-day: Win 56.2%, Sample 16, Median +10.02%, Excess +12.46%, Beat mkt rate 62.5%

120 days after: historical avg +15.69%

20-day +6.82%
60-day +10.61%
120-day +15.69%
20-day
60-day
120-day
Win
52.9%
52.9%
56.2%
Sample
17
17
16
Median
+9.96%
+1.21%
+10.02%
Excess
+6.01%
+8.37%
+12.46%
Beat mkt rate
58.8%
52.9%
62.5%

Over 16 occurrences, 120-day forward avg gained 15.69%, beat the market by 12.46 pts; win rate 56.2%.

Market-wide momentum baseline

Across 98,498 liquid US common-stock samples, top-quintile 6-month momentum was followed by an average 60-trading-day return of +6.12%, a 57.9% positive-return rate, and +2.77 percentage points of average excess return versus the S&P 500.

Baseline: weekly samples since 2016 where a liquid US common stock ranked in the top quintile by 126-trading-day momentum. Forward return is 60 trading days; excess return is versus S&P 500 (^GSPC).

Signals not active now

Inactive signals still show the stock-specific historical forward-return distribution for context.

EPS surprise beat

Pending

Reported EPS beat consensus estimate by at least 5%; event date is the earnings-surprise timestamp.

17 times historically; 60-day forward avg +10.84%, win rate 52.9%, beating the market by +7.73 pts on average.

Continue researching Guardant Health, Inc. with the evidence above.

Continue in Studio ↗

Method and limits

  • Returns use us_price:adj_close, adjusted for splits and dividends where available.
  • Excess returns use world_index:^GSPC as the S&P 500 benchmark proxy.
  • Quarterly fundamentals are aligned to SEC filing dates before daily valuation studies.
  • The promoted universe starts from active NYSE/NASDAQ common stocks, then applies price and dollar-volume gates.
  • Snapshot-only tables such as analyst consensus, DCF, us_ratios, and us_key_metrics are intentionally excluded from historical evidence.
  • Overlapping event windows are descriptive distributions, not independent samples.

This page is for historical data analysis and education only. It is not investment advice. Backtests and historical return distributions do not predict future performance; evaluate risk independently before trading.